Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
823
Views
13
CrossRef citations to date
0
Altmetric
Systematic Review

Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments

Mingjun RuiSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Yingcheng WangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Zhengyang FeiSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Xueke ZhangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Ye ShangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
&
Hongchao LiSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 373-380 | Received 11 Jan 2021, Accepted 17 Feb 2021, Published online: 11 Mar 2021

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Weijia Wu, Shuyi Ding, Zhang Mingming, Zhou Yuping, Xueshan Sun, Zixuan Zhao, Yi Yang, Yongxian Hu & Hengjin Dong. (2023) Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. Journal of Medical Economics 26:1, pages 701-709.
Read now
Zhiwei Zheng, Hongcai Chen, Hongfu Cai & Siqi Xu. (2023) Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-9.
Read now
Zhengyang Fei, Mingjun Rui, Yingcheng Wang & Aixia Ma. (2023) Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research 23:1, pages 79-87.
Read now
Mingjun Rui, Zhengyang Fei, Yingcheng Wang, Xueke Zhang, Aixia Ma, Haikui Sun & Hongchao Li. (2022) Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. Journal of Medical Economics 25:1, pages 618-629.
Read now

Articles from other publishers (9)

Chuan Zhang, Yue Liu, Jing Tan, Panwen Tian & Weimin Li. (2023) Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression. Frontiers in Oncology 13.
Crossref
César Augusto Guevara-Cuellar, Elizabeth Parody-Rúa, María Paula Rengifo-Mosquera, Maria del Mar Conde-Crespo & Jhon Maicol Nuñez-Castro. (2022) Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer in Colombia. Value in Health Regional Issues 32, pages 109-118.
Crossref
Guoliang Shao, Jingwen Wang, Xiaoying Zhou, Guojun Sun & Zuojun Dong. (2022) Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma. Frontiers in Public Health 10.
Crossref
Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Hiroyuki Ohbe, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto & Hideo Yasunaga. (2022) Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. Japanese Journal of Clinical Oncology 52:10, pages 1115-1123.
Crossref
Pingyu Chen, Xintian Wang, Shengwen Zhu, Hongchao Li, Mingjun Rui, Yingcheng Wang, Haikui Sun & Aixia Ma. (2022) Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Frontiers in Public Health 10.
Crossref
Ruizhe Liu, Kaifeng Qiu, Junyan Wu, Yanqing Jiang, Peihao Wu & Jianxin Pang. (2022) Cost–effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma. Immunotherapy 14:11, pages 859-869.
Crossref
Mingjun Rui, Zijing Wang, Zhengyang Fei, Yao Wu, Yingcheng Wang, Lei Sun, Ye Shang & Hongchao Li. (2022) The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China. Frontiers in Pharmacology 13.
Crossref
Jigang Chen, Mingyang Han, Aihua Liu & Bo Shi. (2021) Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US. Frontiers in Oncology 11.
Crossref
Yingcheng Wang, Mingjun Rui, Xin Guan, Yingdan Cao & Pingyu Chen. (2021) Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective. Frontiers in Medicine 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.